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Approximately 20–30% of patients with metastatic germ cell
tumours will not achieve durable remissions after first line treat-
ment (International Germ Cell Cancer Collaborative Group,
1997). Most suffer relapses or disease progression after a
favourable initial response. A variety of salvage chemotherapy
regimens have been used, usually involving a combination of
cisplatin, ifosfamide and perhaps etoposide or vinblastine
(Loehrer et al, 1998). More recently paclitaxel (Motzer et al, 1994)
and gemcitabine (Bokemeyer et al, 1999) have been shown to have
significant activity. Paclitaxel is therefore currently being investi-
gated in combination with ifosfamide and cisplatin as first line
salvage therapy (Motzer et al, 1998). High dose chemotherapy and
stem-cell transplantation has also been successfully utilized for
these patients (Bhatia et al, 1998).
The essential role of surgery in the treatment of relapsed
teratoma is well described (Jansen et al, 1991). Surgery is usually
the treatment of choice in relapse with normal markers. Salvage
surgery is also vital for post-salvage chemotherapy masses, and
can be curative when markers are rising despite salvage
chemotherapy (Murphy et al, 1993). If relapse occurs late (several
years following initial therapy), in the absence of extensive recur-
rence or raised markers, salvage surgery may be the primary mode
of treatment (Baniel et al, 1995).
Overall the results obtained with salvage therapy remain poor.
Reported series indicate that less than 50% of patients will achieve
a favourable response to salvage chemotherapy, with 20–25%
remaining disease free (Loehrer et al, 1998). While the prognosis
of these patients remains unsatisfactory, however, our impression
is that improvements are being made. Our aim has been to report
our most recent experience, and identify prognostic factors for
outcome of relapse.
PATIENTS AND METHODS
This retrospective study comprised all patients treated for NSGCT
between 1991 and 1996 at the Beatson Oncology Centre, Glasgow.
Patient identification was based on West of Scotland cancer regis-
tration. Data were abstracted directly from the patient records. All
patients had received platinum-based primary combination
chemotherapy. The majority of patients had received BEP
(bleomycin, etoposide and cisplatin), or for poorer prognosis
patients BOP-VIP (Kaye et al, 1998) or BOP-BEP (Anthoney et
al, 1999) in clinical trials. Eighteen patients had received carbo-
platin-based chemotherapy within a Medical Research Council
(MRC) randomized trial for good prognosis patients (Horwich et
al, 1997). Patients with residual post-chemotherapy masses had
undergone surgery to remove them by a specific specialist surgical
team with an interest in this tumour type. If residual malignant
disease was identified in the post-chemotherapy resection spec-
imen additional chemotherapy was usually given in the form of
either further cisplatin-based combination chemotherapy or oral
etoposide.
Patients were defined as having achieved CR if, after
chemotherapy, tumour markers and CT scan were normal. Patients
who were marker negative after chemotherapy, and who subse-
quently underwent complete surgical resection of carcinoma or
teratoma were classified as no evidence of disease (NED)carcinoma or
NEDteratoma respectively. Patients with incompletely resected
residual masses were described as having residual carcinoma or
teratoma.
Recurrence was defined on the basis of rising tumour marker
(HCG and/or aFP) and/or the development of new or enlarging
metastases on plain radiographs or computerised tomography
(CT). The salvage treatment utilised depended on the presentation
at relapse and previous treatment. Patients with radiological
evidence of a new lesion but normal markers were managed by
initial surgical resection and did not receive chemotherapy unless
malignant teratoma was seen in the resected specimens. Patients
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initially. The commonest chemotherapy regimen used was VIP:
etoposide, ifosfamide and cisplatin. A number of other regimens
were used including VelP; vinblastine, ifosfamide and cisplatin:
weekly cisplatin and etoposide; and POMB-ACE: cisplatin,
vincristine, methotrexate, bleomycin, actinomycin D, cyclophos-
phamide and etoposide (Bower et al, 1997). The majority of these
patients received between 3 and 6 cycles of chemotherapy (median
4 cycles). Salvage surgery to resect any residual disease was
performed, if necessary, after the completion of chemotherapy.
Radiotherapy was utilized primarily following resection of cere-
bral metastases, although it was also successfully used in one
patient who relapsed with extensive penile, scrotal and inguinal
disease. A further 3 patients with incomplete resection of para-
aortic carcinomatous disease were treated with radiotherapy to the
tumour bed. This was not standard practice and was only utilized
in the absence of other treatment options.
Patients relapsing with rising markers, with evidence of further
response to conventional dose regimes, were considered for entry
into a non-randomised trial of high dose chemotherapy with
peripheral blood stem cell transplantation. High dose
chemotherapy comprised carboplatin (total dose was AUC 20
given over 4 days: d1–4), cyclophosphamide (total dose: 120 mg/
kg divided over d1 and d3), and etoposide (total dose 1.2 g/m2
given over 4 days: d1–4).
After salvage treatment patients were followed up at 2 to 3
monthly intervals in the first year, then 4 to 6 monthly in subse-
quent years, with clinical, radiological and biochemical examina-
tion (aFP, HCG, LDH). Survival times were measured from the
date of diagnosis of progression to the date of death or date last
seen.
Survival times were calculated from the date of diagnosis of
relapse to date of death or date last seen. The Mantel-Haenszel
logrank test was used to examine the prognostic value of the
variables in Table 5. Multivariate analyses were not performed
because of the small number of events involved. Kaplan-Meier
estimates were used for calculating the percent alive at 2 years in
the same table and for drawing the survival curves.
RESULTS
Forty-one patients were treated for relapsed teratoma between
1991 and 1996. Twenty-eight of 41 patients had raised markers at
relapse. The features of these 28 patients at primary diagnosis and
at relapse are presented in Tables 1 and 2. Their median age at
relapse was 29 years, with a median time to relapse of 13 months
(range: 7 to 121 months). Twelve of these 28 patients have died
following treatment for subsequent relapse (Figure 1), 14 (50%)
remain alive with NED. For the 16 living patients the median
follow-up is 72 months (range 26 to 121 months). Table 3
describes the treatment of relapsing disease: all 28 patients were
treated with chemotherapy, with 17 patients having post-
chemotherapy resection of operable residual disease (Table 3). Of
these 17 patients treated with chemotherapy and surgery, 10
remain alive with NED (59%), 2 remain alive with residual
disease, and 5 have died. The other 11 patients were treated with
chemotherapy alone: only 4 (36%) of these patients remain alive in
CR, the rest having died of progressing disease.
An additional 13 patients developed recurrent disease with
normal markers. They were primarily treated surgically (Table 4).
These 13 patients all remain alive with NED, and are not included
in the prognostic factor univariate analyses.
Prognostic factors associated with relapse
A recent study by Fossa et al (1999) identified 3 main factors
predicting a poor prognosis at relapse. These included progres-
sion-free interval (<2 years vs >2 years), response to induction
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Table 1 Characteristics, at initial diagnosis, of patients relapsing with raised markers (n = 28)
Characteristic Group Number of patients (% of total)
Primary site Testicular 25 (89)
Extragonadal 3 (11)
Prognostic group at initial Good 15 (50)
diagnosis (IGCCCG) Intermediate 3 (11)
Poor 10 (39)
Primary chemotherapy BEP 14 (50)
CEB 4 (14)
EP 2 (7)
BOP-BEP 5 (18)
BOP-VIP 2 (7)
PVB 1 (4)
Response to primary Complete remission 12 (43)
chemotherapy. Residual disease 16 (57)
Surgery post-primary Operable residual disease 15
chemotherapy (Patients Para-aortic nodes 11
can have surgery to more Pulmonary metastases 6
than one site) Supraclavicular nodes 3
Brain metastases 1
Inoperable residual disease 1
(liver metastases: malignant on biopsy)
Resection margins at Complete resection 10
above surgery Incomplete resection 5
Pathology of resected Necrosis 5
mass at above surgery Mature teratoma 3
Viable malignant disease 7therapy (CR vs not in CR) and level of serum HCG and aFP at
relapse (<100 or >100). We performed a univariate analysis of
these 3 potential prognostic factors, the results of which are shown
in Table 5. This study confirms that an incomplete response to
primary treatment, resulting in residual unresected disease, is the
most important prognostic parameter. Progression free interval
and level of tumour markers at relapse were not found to be inde-
pendent prognostic factors in our study. When these three prog-
nostic factors are used together, however, patients with 0–1 of
these risk factors were found to have a significantly better
outcome than those with 2–3 risk factors (P = 0.0027).
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Table 2 Characteristics, at relapse, of patients relapsing with raised markers (n = 28)
Patients 28
Age Median 29 years
Range 19–57 years
Remission status obtained Complete remission 12
after initial therapy
Partial remission post-chemotherapy and:
a) necrosis at surgery 5
b) no evaluable disease (NED)teratoma 3
c) NEDcarcinoma 1
d) residual malignant disease 7
Disease free interval <3 months 6
³3 months but <2 years 17
³2 years but <5 years 3
³5 years 2
Markers at Relapse Lowa 14
High 14
aaFP< 100ku/L; HCG< 100 iu/L; LDH < 1.5 ´ normal (17).
Table 3 Treatment at relapse of patients relapsing with raised markers (n = 28)
Treatment of relapse Chemotherapy alone 11 (39%)
Chemotherapy and surgery 17 (61%)
Relapse chemotherapy VP-16, Ifosfamide, Cisplatin (VIP) 16
Taxol, ifosfamide, cisplatin (TIP) 2
Vinblastine, ifosfamide, cisplatin (VnIP) 1
POMB-ACE 2
Other 7
High dose Carboplatin, VP-16 and cyclophosphamide 9
chemotherapy and
PBSCT
Sites of surgery Para-aortic nodes 8
following salvage Pulmonary 7
chemotherapy Brain 3
Retrocrural 0
Pelvic mass 2
Mediastinum 1
Scrotal mass 1
Supraclavicular mass 1
Pathology of surgery Surgical resection margins Pathology
Complete 9 Necrosis 2
Incomplete 5 Mature teratoma 5
Equivocal 3 Malignant 10
Post-operative 3 cycles of oral VP-16-100 mg/day, 14 days q21 5
chemotherapy if resection pathology revealed carcinoma.
Post-operative Para-aortic nodesa 3
radiotherapy Brain 3
Inguinal and scrotala 1
Status Alive in CR 14 (54%)
Alive with residual disease. 2 (3%)
Dead 12 (43%)
aRadiotherapy was only used when this was the only treatment option available to palliate disease.
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Fig.1 Survival curve of patients relapsing with raised markers (n=28)DISCUSSION
A widely accepted prognostic factor based staging system to guide
the treatment of NSGCT patients progressing after induction
cisplatin-based chemotherapy has not yet been defined. A recent
study analysing 164 relapsing patients described an overall
survival rate of 30% (Fossa et al, 1999). This study identified a
number of poor prognostic factors and indicated that treatment in a
large specialist centre could improve outcome.
Indeed our findings do suggest that the outcome of relapsed
NSGCT is improving, and confirm the prognostic significance of
the factors identified by Fossa et al (1999). There are a number of
potential reasons for this improvement in outcome. Firstly, 57%
(94 of 164 patients) of the relapse patients described by Fossa et al
were treated for relapse prior to 1986. Secondly, management of
NSGCT has been shown to have a better outcome in a larger
specialist treatment centre (Harding et al, 1993; Collette et al,
1999). Thirdly, since surgery is a key component of salvage
therapy, access to a specialist surgical team with an interest in
NSGCT is crucial. These results therefore have implications for
future decisions regarding patterns of health care. We propose that
the management of relapsed NSGCT should be carried out with
curative intent, in a specialist unit, with access to a dedicated
specialist surgical team.
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